Joint Formulary & PAD

Botulinum toxin type A - Migraine (prevention)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Not Specified
Associated Icons :
Restrictions / Comments :
Important
Neurology teams only. NOTE; different brands of botulinum toxin have difference licenses, please check SmPC

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Botulinum toxin type A
Indication :
Migraine (prevention)
Group Name :
Keywords :
chronic migraine, migraine prevention, migraine prophylaxis
Brand Names Include :
Botox, Xeomin, Dysport
Important Information :

For Chronic migraine only.

  • RSFT: Neurology only
  • SASH: Botox only Neurology Only
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
0

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends the use of botulinum toxin type A for the prevention of headaches in adults with chronic migraine in line with NICE TA260 (June 2012) and the locally agreed treatment pathway below.

Prescribing will be by hospital specialists only, in line with NICE TA260 using Blueteq initiation and continuation forms. Botulinum toxin type A will be considered RED on the traffic light system.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication